Skip to Content

Fedratinib Approval Status

FDA Approved: No
Generic name: fedratinib
Company: Celgene Corporation
Treatment for: Myelofibrosis

Fedratinib is a highly selective JAK2 inhibitor in development for the treatment of patients with myelofibrosis.

Development Status and FDA Approval Process for fedratinib

DateArticle
Mar  5, 2019U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide